We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ovoca Bio Plc | LSE:OVB | London | Ordinary Share | IE00B4XVDC01 | EUR0.125 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.70 | 0.60 | 0.80 | 0.70 | 0.70 | 0.70 | 26,313 | 08:00:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.46M | -5.61M | -0.0688 | -0.10 | 570.95k |
Date | Subject | Author | Discuss |
---|---|---|---|
01/3/2024 14:32 | hTtps://www.proactiv | mdi | |
01/3/2024 12:20 | Why don’t Ovoca Bio just copy the Futura Medical strategy and seek to get the placebo spray from their failed study just approved as a ‘clinically proven’ medical device spray? Its worked for FUM on paper . Futura have a market Cap of over £119m from generating less then £4m in sales from marketing their placebo as ‘clinically proven’. | mdi | |
02/2/2024 11:10 | As I had difficulty asking questions at the OVB AGM I sent some later by email. Here are their responses which might be of interest. Bear in mind I received their email below on 4th December so it is a couple of months old: [JT 2] Clearly the recent Australian / New Zealand Orenetide trial results were extremely disappointing. It would seem to me that there has either been a flaw in previous trials or in this recent one. Which one is it? [OVB] We strongly disagree that the disappointing results of a recent study mean that there is a flaw in this or the previous studies. Clinical studies are very complex scientific process with risks and uncertain outcome, despite any previous results. This was disclosed in Ovoca’s Re-Admission Document for the Proposed Acquisition of IVIX (Part 2 “Risk factors”, “RISKS RELATING TO THE ENLARGED GROUP AND THE SECTOR IN WHICH IT OPERATES” at p. 19-20): “…Clinic Unfortunately, it seems that this scientific risk has been realized. [JT 3] Who oversaw the previous Russian Orenetide (BP-101) trials? Was it the management of IVIX? [OVB] The previous Russian Orenetide (BP-101) trials were administrated by one of the leading Russian Contract Research Organizations (CRO) – OCT Clinical Trials. Trials Sponsor oversight (which is mandatory according to ICH GCP standard on clinical trials) was done by the management of IVIX. This is public information, but disclosed in the Russian clinical trials registry (however we have checked – automated page translation into English is available in the Chrome browser, and we assume it should be available in other major browsers). Also, public information is available in the Clinicaltrials.gov registry: hxxps://www.clinical [JT 4] Is there any future at all for Orenentide? [OVB] For the moment we are not ready to make any conclusions – study report is still in process, and additional internal assessments are ongoing. The Company will determine the appropriate future strategy regarding the development of Orenetide, including whether the Company can and should continue with its development of this product. [JT 5] What is the future strategy for Ovoca Bio now? [OVB] Again, we are assessing the Orenetide trial results and any implications this may have for the wider strategy of the Company, including a number of potential strategies. We will keep shareholders informed on any developments as and when appropriate. Please keep in mind that while answering to this question we are limited by AIM rules on disclosure of material and insider information, so our reply may not contain any significant comments / material updates beyond anything that already has been published via RNS. | jimtech | |
23/1/2024 07:44 | Great you finally get a RNS and it's a pointless holding RNS from months ago. | dave4545 | |
21/1/2024 11:09 | Almost 5 months and not a word from the company. Would have thought this was plenty of time to decide if to stick or twist with orenetide. | dave4545 | |
08/1/2024 08:59 | This is only just the start. Covid stocks are now all the rage again. | luckyabbeygale | |
04/1/2024 23:08 | It is okay to invest this way when one has a lot of spare money for other stocks. My biggest regret today was not selling some of my non moving shares to invest into Angel first thing at 17p. However I managed to buy £4,000 worth and most likely they be worth more than double tomorrow. I do have a very good feeling about this Ovoca and it is going to take some time, but it will be worth it in the end. | luckyabbeygale | |
04/1/2024 11:45 | You paid all time low my style of investing. Even if they give up on Orenetide there is still a very attractive cash shell route here and they still have Russian assets wether or not they can extract any money from them remains a long shot but they could take a hit and get something for them | dave4545 | |
04/1/2024 11:04 | Wow I am going to take it. As this seems to good an opportunity to miss. I am in for 142277 at 0.84p. | luckyabbeygale | |
04/1/2024 08:20 | 3 months now not a peep, surely by now they must know wether to stick or twist. 0.85p offer online, absolutely dead now which you can expect. | dave4545 | |
21/12/2023 08:26 | Another stock desperate for a update. I'm still holding, the size used to be worth a few quid but now it's a few k so I'll leave it and see if the company becomes a cash shell. But dropping on any sale on L2 atm because in this market there is just no support for dead stocks like this with no news no matter how cheap they look and this one is now valued way below cash levels but what is cash burn now. Not worth selling if you hold still imho not worth averaging down either though | dave4545 | |
05/12/2023 02:13 | The Codger,this company lost over £5 million in 2022 financial year so probably has very little funds left now. | bri15 | |
30/11/2023 11:44 | Wtf are you on mate?obviously sniffing something | the codger | |
30/11/2023 09:56 | Will the mugs on the BOD actually admit today that they were duped in the initial Russian trials, or will they keep stringing everyone along for as long as they can? All they need to do is open source the data from the trials and let some stats students loose on it to give a good indication of how likely it is to be genuine... | esmith3 | |
30/11/2023 07:19 | Agm today.company will have to update on strategy going forward. Otherwise the cashshell option is looming. | the codger | |
02/11/2023 08:32 | No brainer at this level. Cash double of market value. | the codger | |
25/10/2023 19:02 | Somebody got a excellent price today 1.2p or less. | dave4545 | |
24/10/2023 20:10 | wow £937k market cap Despite the setback I think this is becoming heavily oversold but in this market most stocks are with no buyers out there and prices getting slashed on just a fraction of sales it would take previously to knock it down. | dave4545 | |
19/9/2023 15:11 | Shameless ramper dave4545 still ramping this one. As soon as there is a spike, he is going to dump | optmist | |
12/9/2023 07:16 | £1.5 mil market cap recent cash £2.2 mil Lots of tax losses, if they give up on the drug it could be a very attractive cash shell. Still they might find a reason for such poor trial results and continue who knows. Just think it's a fraction oversold now | dave4545 | |
05/9/2023 10:43 | More carnage. Hope everyone keeps away from dave4545 advice | optmist | |
01/9/2023 14:55 | I just thought Id post it from the other site. Made me think a bit about it. Cheers for the replies. | recordz | |
01/9/2023 14:39 | Interesting H | dave4545 | |
01/9/2023 14:25 | "a bit strange" Sub 2020 yes...After 2021 no Look at the data in the covid vaccine trials and they got approval...shocking ! So who knows who is telling the truth and who is lying here when it comes to this trial and the old Russian one from 2017 | dave4545 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions